InflaRx to Participate in Upcoming Investor Conferences

Rhea-AI Summary

InflaRx (IFRX) has announced its participation in three major investor conferences in June and July 2025. The company will present at the Jefferies Global Healthcare Conference on June 4th at 7:35 AM ET, participate in a dermatology panel at the Oppenheimer Innovators in I&I Summit on June 25th, and conduct one-on-one meetings at the Leerink Partners Therapeutics Forum on July 8th. InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, developing treatments targeting the complement system. Their lead product, vilobelimab, is an intravenous anti-C5a monoclonal antibody, while INF904 is their oral small molecule C5a receptor inhibitor in development.

JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple investor conferences in June and July 2025.

Jefferies Global Healthcare Conference
June 3 - 5, 2025 in New York, NY

InflaRx will conduct an investor presentation on June 4th at 7:35 AM ET and will participate in one-on-one investor meetings. A link to register for the presentation live stream and its replay is available here.

Oppenheimer Innovators in I&I Summit
June 25, 2025 in New York, NY

InflaRx will participate in a panel - Advances in Dermatology: AD and CSU – being held 10:45-11:20 AM ET, as well as participate in one-on-one investor meetings.

Leerink Partners Therapeutics Forum: I&I and Metabolism
July 8 - 9, 2025 in Boston, MA
One-on-one investor meetings on June 8.

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

What investor conferences will IFRX attend in June and July 2025?

IFRX will attend three conferences: Jefferies Global Healthcare Conference (June 3-5), Oppenheimer Innovators in I&I Summit (June 25), and Leerink Partners Therapeutics Forum (July 8-9).

What is InflaRx's (IFRX) main product candidate?

InflaRx's lead product candidate is vilobelimab, a first-in-class, intravenous anti-C5a monoclonal antibody that has shown disease-modifying clinical activity in multiple studies.

What therapeutic area does InflaRx (IFRX) focus on?

InflaRx focuses on anti-inflammatory therapeutics by targeting the complement system, specifically the C5a and C5aR pathway.

When will IFRX present at the Jefferies Healthcare Conference 2025?

IFRX will present at the Jefferies Global Healthcare Conference on June 4th, 2025, at 7:35 AM ET.